Gilead wins reversal of $1.2B fine against Bristol Myers in patent case

 Gilead Sciences Inc GILD.O escaped a $1.2 billion fine, after the Federal Circuit Court of Appeals on Thursday found the relevant parts of a Bristol Myers Squibb BMY.N patent that Gilead's Yescarta cancer drug allegedly infringed were invalid.

Last year, a federal judge increased the damages that Gilead would pay to Bristol Myers Squibb to $1.2 billion in a patent infringement case related to CAR T-cell immunotherapy for cancer.

https://www.nasdaq.com/articles/gilead-sciences-wins-reversal-of-%241.2-bln-fine-against-bristol-myers-in-patent-case-2021